Our next-generation sequencing (NGS) platform enables comprehensive analysis of genetic and transcriptomic information to support target discovery and drug development. Using state-of-the-art sequencing instruments, we generate high-resolution data on gene expression, mutations, and regulatory networks, providing insights into disease biology and therapeutic mechanisms. Automated library preparation, high-throughput sequencing, and integrated bioinformatics pipelines ensure accuracy, reproducibility, and scalability to deliver the depth of data needed to accelerate modern drug discovery.

Our cell culture and organism platforms provide versatile systems to evaluate drug candidates in physiologically relevant contexts. We maintain mammalian cell lines, primary cells, and engineered models to study target biology, drug efficacy, and toxicity under controlled conditions. Complementing these, microbial and other model organisms are employed for natural product biosynthesis, pathway engineering, and early functional screening. Together, these systems create a robust foundation for translating molecular insights into validated biological outcomes.

Automation underpins our ability to scale discovery efficiently and reproducibly. By integrating robotic liquid handling, automated high-throughput screening platforms, and advanced sample management systems, we streamline complex experimental workflows from protein expression and NGS library preparation to cell-based assays. This reduces variability, accelerates turnaround times, and enables the generation of large, high-quality datasets that feed directly into our computational and AI-driven analytics. Automation ensures our scientists can focus on innovation while the infrastructure delivers precision and throughput at scale.